DB00082 Pfizer/Sensus . Pfizer ( formerly Pharmacia ) , in collaboration with its wholly owned subsidiary Sensus , has developed and launched pegvisomant , a pegylated , genetically modified human growth hormone ( hGH ) , for the treatment of acromegaly . DB00082 , in contrast to classical somatostatin analogs which lower hGH synthesis , exerts its anti-hGH action by preventing P10912 activation . This drug is now available in the US and Europe for the treatment of acromegaly .